RCS - Belluscura PLC - Third US Distribution Agreement

BelluscuraAnnouncement

13/07/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210713:nRSM9343Ea&default-theme=true

RNS Number : 9343E  Belluscura PLC  13 July 2021

Belluscura PLC

("Belluscura" or the "Company" or "Group")

 

Third US Distribution Agreement

 

LONDON, U.K. AND PLANO, TX, U.S. (13 July 2021).  Belluscura plc (AIM: BELL),
a leading medical device developer focused on lightweight and portable oxygen
enrichment technology, announces the signing of its third distribution
agreement and first agreement with a durable medical equipment ("DME")
provider, for its X-PLO(2)R™ portable oxygen concentrator ("POC") portfolio.
This is the next stage in establishing US-wide distribution coverage as part
of the Group's commercialisation strategy.

The provider, a DME located in the upper Midwest US, has multiple stores in
several states and an online store.  The distributor issued its first
purchase order with anticipated delivery of the X-PLO(2)R™ portable oxygen
concentrator expected in less than ninety days.

As described in the Company's Admission Document, Belluscura's plan is to
appoint distributors in the US to give US-wide coverage for the launch of the
X-PLO(2)R™; and this is expected to occur in the second half of 2021 and
into 2022.

 

About the X-PLO₂R™

The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it
is the world's first modular portable oxygen concentrator and that it will
generate more oxygen by weight than any other US Food & Drug
Administration ("FDA") cleared POC in its class. The X-PLO(2)R™ can deliver
up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help
improve the quality of life for millions of people worldwide who suffer from
chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and
respiratory distress caused by COVID-19. The X-PLO₂R™ is designed to
replace larger, metal oxygen tanks and heavier portable oxygen concentrator
devices.

 

In March 2021 Belluscura received 510(k) clearance from the FDA for the
X-PLO(2)R™, which will be launched commercially in Q3 2021. Additional
products within the range will be launched within the next 12 months.

Robert Rauker, CEO of Belluscura plc, said: "Having the X-PLO(2)R™ portable
oxygen concentrator available in stores for potential customers to hold and
feel, we believe, will help drive sales of the units. We look forward to
commercial launch which we anticipate to start in just a few months."

 

For further information please contact:

 

 Belluscura plc                                    www.belluscura.com (http://www.belluscura.com)
 Robert Rauker, Chief Executive Officer            via Walbrook PR
 Anthony Dyer, Chief Financial Officer

 SPARK Advisory Partners Limited (NOMAD)           Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Dowgate Capital Limited (Broker)                  Tel: +44 (0)20 3903 7715
 James Serjeant / Nicholas Chambers

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Belluscura plc (www.belluscura.com (http://www.belluscura.com) )

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLLFFFDLLBBV